VALTURNA
Post-LOENDAORALTABLET
Approved
Sep 2009
Lifecycle
Post-LOE
Competitive Pressure
35/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 11h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VALTURNA is an oral tablet combining two antihypertensive agents approved by the FDA in 2009 as a fixed-dose combination for hypertension management. The exact mechanism of action and pharmacologic class are not specified in available data, but the product represents a small-molecule oral formulation. It is used to reduce blood pressure in patients who require dual-agent therapy.
Post-LOEPost-LOE
Product is in post-LOE phase with moderate competitive pressure (35 score), indicating a mature, stable market with smaller sales and support teams focused on retention and lifecycle extension.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes
Started May 2011
975 enrolled
HypertensionStage 2 HypertensionDiabetes
Why This Matters for Your Career
Worked on VALTURNA at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.